Evidence map›Paper›PMID 40847689›Full record

ArticleJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2025

Low-dose total skin electron beam therapy in erythrodermic mycosis fungoides and Sézary syndrome: Results From the Prospective S-MISR Study.

Khaled Elsayad, Christian Kandler, Jan Jakob Siats, Niklas Pepper, Moritz Fabian Danzer, Gabor Dobos, Elisabeth Livingstone, Susanne Melchers, Johannes Kleemann, Julia Hyun and 5 more

Abstract read
In one paragraph

Article in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Low-dose total skin electron beam therapy in erythrodermic mycosis fungoides and Sézary syndrome: Results From the Prospective S-MISR Study.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Khaled ElsayadDepartment of Radiation Oncology, University Hospital Münster, Münster, Germany.ORCID 0000-0001-9303-7336
Christian KandlerDepartment of Radiation Oncology, University Hospital Münster, Münster, Germany.
Jan Jakob SiatsDepartment of Radiation Oncology, University Hospital Münster, Münster, Germany.
Niklas PepperDepartment of Radiation Oncology, University Hospital Münster, Münster, Germany.
Moritz Fabian DanzerInstitute of Biostatistics and Clinical Research, University of Münster, Münster, Germany.
Gabor DobosClinic for Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.ORCID 0000-0002-2544-7197
Elisabeth LivingstoneDepartment of Dermatology, University Hospital Essen, Essen, Germany.
Susanne MelchersDepartment of Dermatology, Venereology and Allergology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.
Johannes KleemannDepartments of Dermatology, Venereology and Allergy, Goethe University, Frankfurt am Main, Germany.
Julia HyunDepartment of Dermatology, Venereology, and Allergology, Helios St. Johannes Hospital Duisburg, Duisburg, Germany.
Claudia PföhlerSaarland University Medical Center, Deparment of Dermatology, Homburg/Saar, Germany.
Peter von den DrieschDepartment of Dermatology, Klinikum Stuttgart, Bad Cannstatt, Stuttgart, Germany.
Jan P NicolayDepartment of Dermatology, Venereology and Allergology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.
Rudolf StadlerUniversity Department for Dermatology, Venerology, Allergology and Phlebology, Skin Cancer Center, Johannes Wesling Medical Center, UKRUB, University of Bochum, Minden, Germany.ORCID 0000-0003-2683-6028
Hans Theodor EichDepartment of Radiation Oncology, University Hospital Münster, Münster, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundErythrodermic mycosis fungoides (eMF) and Sézary syndrome (SS) often show delayed and non-durable clinical responses to systemic therapies. PATIENTS AND

methodsA total of 35 patients with eMF or SS were treated with total skin electron beam therapy (TSEBT). Response rates, patient-reported outcomes, survival data, median time to next treatment (TTNT), and progression-free survival (PFS) were evaluated.

resultsThe analysis included 21 patients with SS and 14 with eMF. The median radiation dose was 12 Gy. At 3 months post-TSEBT, the overall response rate was 89%. A total of 25 patients (71%) required subsequent systemic therapy. The median TTNT was 20 months, and the median PFS was 14 months. Patients reported marked reductions in pruritus, decreased skin disease burden, and improved health-related quality of life scores. Notably, both TTNT and PFS were longer in patients who received subsequent therapy compared to those who did not. Grade ≥3 radiation-related toxicity was observed in 6% of patients. In the translational arm of the study, several potential peripheral blood biomarkers were identified.

conclusionsLow-dose TSEBT is an effective treatment option for patients with eMF and SS, facilitating subsequent therapies and enabling long-term disease control. The treatment is associated with significant quality-of-life improvements and low toxicity.

Indexed as

ElectronsMycosis FungoidesSezary SyndromeSkin NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedProspective StudiesQuality of LifeRadiotherapy DosageTreatment Outcomeblood involvementhealth‐related quality of lifeimmunotherapyleukemic typepruritusRadiotherapyS‐MISR registry

Identifiers

PMID40847689
PMCPMC12697321

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.